AbbVie announces that it has completed the acquisition of ImmunoGen, whose portfolio of products 'complements AbbVie's existing oncology portfolio and has the potential to transform multiple solid tumors and hematological malignancies'.

The transaction gives the healthcare group access to Elahere, the first and only antibody-drug conjugate approved by the US FDA for the treatment of ovarian cancer.

AbbVie confirms its full-year 2024 adjusted EPS target range of $11.05-11.25, but lowers its first-quarter range by four cents to between $2.26 and $2.30, due to the acquisition of ImmunoGen.

Copyright (c) 2024 All rights reserved.